Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a chest scan shortcut dangerous heart rhythm surgery?

NCT ID NCT07759427

Disease control Sponsor: University of Warwick Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether a non-invasive mapping system called VIVO can help doctors locate the source of a dangerous heart rhythm called ventricular tachycardia (VT) before an invasive procedure. Patients with structural heart disease who need catheter ablation will be randomly assigned to receive either standard ablation or VIVO-guided ablation. The goal is to see if VIVO reduces procedure time and improves efficiency, while also assessing safety and patient outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VIVO-assisted mapping, a non-invasive cardiac mapping technology used to guide catheter ablation for ventricular tachycardia
What this could lead to
If successful, this approach could make VT ablation faster, safer, and more efficient, potentially improving outcomes for patients with structural heart disease.
What could go wrong
The trial is relatively small and early, and the benefit may not be confirmed. The procedure still involves invasive ablation, which carries risks like bleeding or heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years old * Patient with the following: * Evidence of post-myocardial infarction\* structural heart disease. * Cardiac CT and/or cardiac MRI scan performed within 6 months. * ICD/CRTD implantation. * Device therapy for VT: at least 1 appropriate ICD shock or 3 ATP episodes within a 6-month period. * Suitable candidate for VT ablation as per NHS standard of care. * Patient agrees to comply with study procedures and be available for routine follow up visits for at least 6 months after enrolment. Exclusion Criteria: * Lacks capacity to provide informed consent. * Presence of intramural thrombus, tumour or abnormality that precludes vascular access, catheter introduction or manipulations. * Coagulopathy, bleeding diathesis or suspected pro-coagulant state. * Sepsis, active systemic infection or fever (\>100.5 F/38 C) within a week prior to the ablation procedure. * Renal failure requiring dialysis or renal compromise that in the investigator's judgement would increase risk to the patient or deem the patient inappropriate to participate in the study. * Known allergies or intolerance to AADs to be used to treat PVCs. * Known allergy for contrast. * Female patients who are pregnant or breast feeding. * Enrolment in a concurrent interventional clinical study that in the judgement of the investigator would increase risk to the patient or deem them inappropriate to participate in this study. * Other conditions that may prevent patients from adhering to the study protocol, in the opinion of the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Catheter ablation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Catheter ablation Ventricular tachycardia (VT)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Royal Sussex County Hospital

    NOT_YET_RECRUITING

    Brighton, BN2 1ES, United Kingdom

  • The James Cook University Hospital

    RECRUITING

    Middlesbrough, TS4 3B, United Kingdom

  • University Hospitals Coventry and Warwickshire

    RECRUITING

    Coventry, CV2 2DX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.